company background image
SFA logo

Sopharma AD BUL:SFA Stock Report

Last Price

лв5.78

Market Cap

лв957.9m

7D

-0.3%

1Y

-19.5%

Updated

20 Nov, 2024

Data

Company Financials

Sopharma AD

BUL:SFA Stock Report

Market Cap: лв957.9m

SFA Stock Overview

Produces, distributes, and exports pharmaceutical products in Europe, Bulgaria, and internationally. More details

SFA fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance2/6
Financial Health5/6
Dividends3/6

Rewards

Price-To-Earnings ratio (12.3x) is below the BG market (17.2x)

Risk Analysis

Shareholders have been diluted in the past year

Dividend of 2.6% is not well covered by free cash flows


Sopharma AD Competitors

DHG Pharmaceutical

HOSE:DHG

₫13.0t

Hunan Warrant PharmaceuticalLtd

SHSE:688799

CN¥3.9b

Jiangxi Synergy Pharmaceutical

SZSE:300636

CN¥3.6b

Morepen Laboratories

BSE:500288

₹41.6b

Price History & Performance

Summary of all time highs, changes and price drops for Sopharma AD
Historical stock prices
Current Share Priceлв5.78
52 Week Highлв7.24
52 Week Lowлв5.58
Beta-0.041
11 Month Change-1.70%
3 Month Change-2.03%
1 Year Change-19.50%
33 Year Change35.68%
5 Year Change72.54%
Change since IPO-6.58%

Recent News & Updates

Sopharma AD's (BUL:SFA) Problems Go Beyond Weak Profit

Sep 07
Sopharma AD's (BUL:SFA) Problems Go Beyond Weak Profit

Recent updates

Sopharma AD's (BUL:SFA) Problems Go Beyond Weak Profit

Sep 07
Sopharma AD's (BUL:SFA) Problems Go Beyond Weak Profit

Here's Why Sopharma AD (BUL:SFA) Can Manage Its Debt Responsibly

Jun 02
Here's Why Sopharma AD (BUL:SFA) Can Manage Its Debt Responsibly

Sopharma AD (BUL:SFA) Has A Somewhat Strained Balance Sheet

Apr 09
Sopharma AD (BUL:SFA) Has A Somewhat Strained Balance Sheet

Here's Why We Think Sopharma AD (BUL:3JR) Is Well Worth Watching

Feb 20
Here's Why We Think Sopharma AD (BUL:3JR) Is Well Worth Watching

How Many Sopharma AD (BUL:3JR) Shares Do Institutions Own?

Feb 05
How Many Sopharma AD (BUL:3JR) Shares Do Institutions Own?

Should You Rely On Sopharma AD's (BUL:3JR) Earnings Growth?

Jan 22
Should You Rely On Sopharma AD's (BUL:3JR) Earnings Growth?

Sopharma AD (BUL:3JR) Has A Somewhat Strained Balance Sheet

Jan 06
Sopharma AD (BUL:3JR) Has A Somewhat Strained Balance Sheet

Sopharma AD (BUL:3JR) Share Prices Have Dropped 25% In The Last Three Years

Dec 22
Sopharma AD (BUL:3JR) Share Prices Have Dropped 25% In The Last Three Years

Should Sopharma AD (BUL:3JR) Be Part Of Your Dividend Portfolio?

Dec 07
Should Sopharma AD (BUL:3JR) Be Part Of Your Dividend Portfolio?

Are Investors Undervaluing Sopharma AD (BUL:3JR) By 29%?

Nov 19
Are Investors Undervaluing Sopharma AD (BUL:3JR) By 29%?

Should Sopharma AD (BUL:3JR) Be Part Of Your Dividend Portfolio?

Jul 07
Should Sopharma AD (BUL:3JR) Be Part Of Your Dividend Portfolio?

Shareholder Returns

SFABG PharmaceuticalsBG Market
7D-0.3%-3.0%0.06%
1Y-19.5%4.3%10.2%

Return vs Industry: SFA underperformed the BG Pharmaceuticals industry which returned 3.6% over the past year.

Return vs Market: SFA underperformed the BG Market which returned 10% over the past year.

Price Volatility

Is SFA's price volatile compared to industry and market?
SFA volatility
SFA Average Weekly Movement2.4%
Pharmaceuticals Industry Average Movement5.3%
Market Average Movement4.0%
10% most volatile stocks in BG Market8.2%
10% least volatile stocks in BG Market2.6%

Stable Share Price: SFA has not had significant price volatility in the past 3 months compared to the BG market.

Volatility Over Time: SFA's weekly volatility (2%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19334,896Ognian Donevwww.sopharmagroup.com

Sopharma AD produces, distributes, and exports pharmaceutical products in Europe, Bulgaria, and internationally. The company operates through Production of Pharmaceutical Products; Distribution of Pharmaceutical Products (Goods); and Others. It offers Carsil to treat liver disease; Tempalgin and Analgin, a painkiller; Tabex, drug used for smoking secession; Tribestan, drug used for stimulation of the male reproductive system; Broncholytin, which is used to suppress cough; Nivalin, used for diseases of the peripheral nervous system; Methylprednisolon, for severe allergies and life-threatening conditions; Vitamin C; Valeriana, used to reduce the stress; and medical devices, such as gauzes, compresses, and dressing.

Sopharma AD Fundamentals Summary

How do Sopharma AD's earnings and revenue compare to its market cap?
SFA fundamental statistics
Market capлв957.91m
Earnings (TTM)лв77.60m
Revenue (TTM)лв1.97b

12.3x

P/E Ratio

0.5x

P/S Ratio

Is SFA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SFA income statement (TTM)
Revenueлв1.97b
Cost of Revenueлв1.54b
Gross Profitлв429.34m
Other Expensesлв351.75m
Earningsлв77.60m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

Jan 30, 2025

Earnings per share (EPS)0.47
Gross Margin21.75%
Net Profit Margin3.93%
Debt/Equity Ratio33.3%

How did SFA perform over the long term?

See historical performance and comparison

Dividends

2.6%

Current Dividend Yield

32%

Payout Ratio

Does SFA pay a reliable dividends?

See SFA dividend history and benchmarks
When do you need to buy SFA by to receive an upcoming dividend?
Sopharma AD dividend dates
Ex Dividend DateNov 07 2024
Dividend Pay DateDec 23 2024
Days until Ex dividend14 days
Days until Dividend pay date32 days

Does SFA pay a reliable dividends?

See SFA dividend history and benchmarks